FY2019 EPS Estimates for Becton Dickinson and Co Decreased by William Blair (BDX)

Becton Dickinson and Co (NYSE:BDX) – Equities researchers at William Blair decreased their FY2019 earnings per share estimates for shares of Becton Dickinson and in a research note issued to investors on Tuesday, November 6th. William Blair analyst B. Weinstein now expects that the medical instruments supplier will post earnings of $12.10 per share for the year, down from their previous estimate of $12.50. William Blair also issued estimates for Becton Dickinson and’s Q2 2020 earnings at $3.41 EPS and Q4 2020 earnings at $3.77 EPS.

Several other research firms have also issued reports on BDX. Wells Fargo & Co dropped their price objective on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday. Barclays set a $260.00 price objective on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday. Morgan Stanley increased their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. KeyCorp reiterated a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, Citigroup increased their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $254.07.

Becton Dickinson and stock opened at $243.26 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. Becton Dickinson and has a 52-week low of $209.91 and a 52-week high of $265.87. The firm has a market cap of $63.38 billion, a price-to-earnings ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the prior year, the company posted $2.40 earnings per share. The business’s revenue for the quarter was up 39.0% compared to the same quarter last year.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Becton Dickinson and by 1.3% in the third quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock valued at $4,966,582,000 after buying an additional 253,041 shares in the last quarter. FMR LLC boosted its holdings in Becton Dickinson and by 8.0% in the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after acquiring an additional 1,286,579 shares during the last quarter. Fundsmith Equity Fund L.P. bought a new position in Becton Dickinson and in the second quarter valued at about $894,775,000. Wells Fargo & Company MN boosted its holdings in Becton Dickinson and by 0.8% in the third quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock valued at $930,491,000 after acquiring an additional 27,188 shares during the last quarter. Finally, Putnam Investments LLC boosted its holdings in Becton Dickinson and by 0.5% in the second quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock valued at $841,690,000 after acquiring an additional 18,859 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

In other news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares in the company, valued at $22,210,614.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP James C. Lim sold 5,189 shares of the firm’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the sale, the executive vice president now owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Discount Rate

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply